

**REMARKS**

In response to the Restriction Requirement set forth in the Office Action mailed February 25, 2008, Applicants hereby elect Group I (claims 1-16) for continued examination. The Examiner has further required election of a single antigen or combination of antigens ( $\beta$ -1,2 oligomannoside, FHENWPS, ICAM-2, ICAM-3, or antibodies that bind DC-SIGN) if Group I is elected. Applicants hereby elect antibodies that bind DC-SIGN.


Applicants have amended the claims to direct them to the elected invention. In particular, claims 1, 2, 11, 12, and 16 have been amended to recite an antibody that binds to DC-SIGN. Claims 1-8, 10-12, and 16 are readable on the elected invention. Claims 9, 13-15, and 17-32 have been canceled, without prejudice.

Applicant reserves the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions. Applicant does not hereby abandon or waive any rights in the non-elected inventions.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 18-1945, under Order No. ALXN-P01-093 from which the undersigned is authorized to draw.

Dated: March 25, 2008

Respectfully submitted,

By 

Tianxin (Cynthia) Chen, Ph.D., J.D.

Registration No.: 61,193

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant